| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cerebral Amyloid Angiopathy | 201 | 2024 | 859 | 30.420 |
Why?
|
| Cerebral Hemorrhage | 247 | 2024 | 2647 | 18.510 |
Why?
|
| Cerebral Amyloid Angiopathy, Familial | 23 | 2024 | 53 | 4.490 |
Why?
|
| Siderosis | 18 | 2023 | 102 | 4.220 |
Why?
|
| Amyloid beta-Peptides | 59 | 2023 | 3587 | 3.810 |
Why?
|
| Cerebral Infarction | 13 | 2020 | 1011 | 3.330 |
Why?
|
| Hematoma | 33 | 2023 | 758 | 3.030 |
Why?
|
| Brain | 105 | 2023 | 26388 | 2.830 |
Why?
|
| Stroke | 52 | 2023 | 9981 | 2.390 |
Why?
|
| Magnetic Resonance Imaging | 158 | 2024 | 35425 | 2.090 |
Why?
|
| Intracranial Hemorrhages | 15 | 2021 | 855 | 2.050 |
Why?
|
| Alzheimer Disease | 57 | 2023 | 8038 | 1.930 |
Why?
|
| Apolipoproteins E | 31 | 2022 | 1438 | 1.700 |
Why?
|
| Dementia, Vascular | 8 | 2023 | 129 | 1.700 |
Why?
|
| Anticoagulants | 32 | 2023 | 4600 | 1.640 |
Why?
|
| Microvessels | 7 | 2019 | 544 | 1.570 |
Why?
|
| Amyloid beta-Protein Precursor | 19 | 2023 | 1121 | 1.500 |
Why?
|
| Cerebral Angiography | 21 | 2021 | 1285 | 1.470 |
Why?
|
| Brain Ischemia | 16 | 2021 | 3265 | 1.460 |
Why?
|
| Cognition Disorders | 26 | 2017 | 4043 | 1.430 |
Why?
|
| Hemosiderosis | 6 | 2020 | 71 | 1.380 |
Why?
|
| Aged | 263 | 2024 | 163288 | 1.350 |
Why?
|
| Warfarin | 22 | 2019 | 1497 | 1.320 |
Why?
|
| Dementia | 21 | 2022 | 2518 | 1.320 |
Why?
|
| Leukoaraiosis | 6 | 2022 | 120 | 1.250 |
Why?
|
| Aged, 80 and over | 145 | 2023 | 57776 | 1.230 |
Why?
|
| Nerve Fibers, Myelinated | 6 | 2019 | 957 | 1.200 |
Why?
|
| Cerebral Cortex | 23 | 2020 | 5709 | 1.180 |
Why?
|
| Amyloidosis | 6 | 2023 | 796 | 1.160 |
Why?
|
| Brain Infarction | 7 | 2021 | 299 | 1.120 |
Why?
|
| Humans | 445 | 2024 | 744366 | 1.100 |
Why?
|
| Minocycline | 3 | 2024 | 163 | 1.010 |
Why?
|
| Male | 288 | 2024 | 350115 | 1.000 |
Why?
|
| Cerebrovascular Disorders | 15 | 2022 | 1504 | 0.970 |
Why?
|
| Amyloid | 9 | 2023 | 795 | 0.950 |
Why?
|
| Subarachnoid Hemorrhage | 8 | 2021 | 1018 | 0.930 |
Why?
|
| Apolipoprotein E4 | 18 | 2023 | 668 | 0.930 |
Why?
|
| Middle Aged | 193 | 2024 | 213390 | 0.910 |
Why?
|
| Aniline Compounds | 8 | 2022 | 986 | 0.900 |
Why?
|
| Female | 268 | 2024 | 380193 | 0.860 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 13 | 2023 | 2737 | 0.810 |
Why?
|
| Peptide Fragments | 17 | 2023 | 5096 | 0.790 |
Why?
|
| Hypertension | 26 | 2023 | 8479 | 0.780 |
Why?
|
| Thiazoles | 7 | 2019 | 1483 | 0.730 |
Why?
|
| Cohort Studies | 73 | 2024 | 40559 | 0.710 |
Why?
|
| Cerebral Arteries | 9 | 2017 | 494 | 0.710 |
Why?
|
| Tomography, X-Ray Computed | 42 | 2023 | 20130 | 0.700 |
Why?
|
| Nervous System Diseases | 3 | 2021 | 1622 | 0.690 |
Why?
|
| Disease Progression | 35 | 2021 | 13286 | 0.680 |
Why?
|
| Apolipoprotein E2 | 12 | 2019 | 127 | 0.670 |
Why?
|
| Amyloidogenic Proteins | 3 | 2023 | 152 | 0.640 |
Why?
|
| Blood Vessels | 8 | 2020 | 1125 | 0.630 |
Why?
|
| Positron-Emission Tomography | 12 | 2022 | 6234 | 0.600 |
Why?
|
| Ischemic Attack, Transient | 2 | 2021 | 935 | 0.600 |
Why?
|
| Diffusion Tensor Imaging | 13 | 2023 | 2305 | 0.600 |
Why?
|
| Blood Transfusion | 1 | 2023 | 1301 | 0.580 |
Why?
|
| Atrial Fibrillation | 13 | 2023 | 5035 | 0.570 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 9 | 2015 | 3255 | 0.550 |
Why?
|
| Longitudinal Studies | 34 | 2023 | 13991 | 0.550 |
Why?
|
| Leukoencephalopathies | 5 | 2022 | 238 | 0.550 |
Why?
|
| Occipital Lobe | 6 | 2021 | 379 | 0.540 |
Why?
|
| Microcirculation | 5 | 2015 | 1287 | 0.520 |
Why?
|
| Image Processing, Computer-Assisted | 26 | 2021 | 8949 | 0.520 |
Why?
|
| Platelet Aggregation Inhibitors | 7 | 2023 | 3070 | 0.510 |
Why?
|
| Heterozygote | 4 | 2021 | 2804 | 0.510 |
Why?
|
| Plaque, Amyloid | 10 | 2023 | 729 | 0.510 |
Why?
|
| Meninges | 5 | 2020 | 190 | 0.500 |
Why?
|
| Brain Diseases | 2 | 2023 | 1563 | 0.500 |
Why?
|
| Hematoma, Epidural, Cranial | 2 | 2013 | 60 | 0.490 |
Why?
|
| Hemorrhage | 7 | 2023 | 3461 | 0.480 |
Why?
|
| Collagen Type IV | 3 | 2012 | 140 | 0.460 |
Why?
|
| Antihypertensive Agents | 7 | 2021 | 2047 | 0.460 |
Why?
|
| Risk Factors | 72 | 2022 | 72296 | 0.460 |
Why?
|
| Arteriolosclerosis | 2 | 2023 | 21 | 0.450 |
Why?
|
| Retrospective Studies | 59 | 2024 | 77460 | 0.450 |
Why?
|
| Recurrence | 21 | 2021 | 8340 | 0.440 |
Why?
|
| Immunosuppressive Agents | 5 | 2020 | 4153 | 0.440 |
Why?
|
| American Heart Association | 7 | 2022 | 1057 | 0.440 |
Why?
|
| Neurodegenerative Diseases | 5 | 2023 | 1061 | 0.440 |
Why?
|
| Executive Function | 7 | 2023 | 1364 | 0.440 |
Why?
|
| Cerebrovascular Circulation | 7 | 2020 | 2732 | 0.430 |
Why?
|
| Prospective Studies | 60 | 2023 | 53290 | 0.430 |
Why?
|
| Awards and Prizes | 1 | 2017 | 375 | 0.430 |
Why?
|
| Memory Disorders | 4 | 2021 | 1186 | 0.420 |
Why?
|
| Cerebellar Diseases | 3 | 2021 | 226 | 0.410 |
Why?
|
| Inflammation | 11 | 2023 | 10637 | 0.400 |
Why?
|
| Neural Pathways | 7 | 2017 | 2974 | 0.400 |
Why?
|
| Antibodies, Monoclonal | 4 | 2023 | 9274 | 0.390 |
Why?
|
| Heparinoids | 1 | 2010 | 7 | 0.390 |
Why?
|
| Receptors, Cytokine | 1 | 2012 | 262 | 0.390 |
Why?
|
| Autopsy | 9 | 2020 | 1020 | 0.390 |
Why?
|
| Blood Pressure | 11 | 2022 | 8551 | 0.380 |
Why?
|
| Oxadiazoles | 1 | 2010 | 93 | 0.380 |
Why?
|
| Axons | 1 | 2019 | 1685 | 0.380 |
Why?
|
| Benzopyrans | 1 | 2010 | 64 | 0.370 |
Why?
|
| Genotype | 34 | 2022 | 12952 | 0.360 |
Why?
|
| Genetic Predisposition to Disease | 18 | 2019 | 17446 | 0.360 |
Why?
|
| Benzenesulfonates | 1 | 2010 | 169 | 0.360 |
Why?
|
| International Normalized Ratio | 6 | 2017 | 367 | 0.350 |
Why?
|
| Decision Support Techniques | 4 | 2011 | 1956 | 0.350 |
Why?
|
| Case-Control Studies | 27 | 2022 | 21748 | 0.350 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 5 | 1999 | 494 | 0.340 |
Why?
|
| tau Proteins | 8 | 2021 | 1868 | 0.340 |
Why?
|
| Posterior Cerebral Artery | 1 | 2008 | 24 | 0.330 |
Why?
|
| Neuropsychological Tests | 16 | 2021 | 6994 | 0.320 |
Why?
|
| Magnetic Resonance Angiography | 6 | 2017 | 1443 | 0.320 |
Why?
|
| Predictive Value of Tests | 24 | 2020 | 15078 | 0.310 |
Why?
|
| Anisotropy | 4 | 2019 | 1265 | 0.300 |
Why?
|
| Threonine | 1 | 2008 | 279 | 0.300 |
Why?
|
| Bronchodilator Agents | 1 | 2010 | 502 | 0.290 |
Why?
|
| Prognosis | 27 | 2023 | 29060 | 0.290 |
Why?
|
| Clinical Trials as Topic | 10 | 2021 | 7914 | 0.290 |
Why?
|
| Diffuse Axonal Injury | 2 | 2017 | 49 | 0.290 |
Why?
|
| Prealbumin | 1 | 2008 | 210 | 0.290 |
Why?
|
| Polymyositis | 1 | 2007 | 75 | 0.280 |
Why?
|
| Corpus Callosum | 4 | 2022 | 737 | 0.280 |
Why?
|
| Brain Stem Hemorrhage, Traumatic | 2 | 2017 | 13 | 0.280 |
Why?
|
| Proline | 1 | 2008 | 458 | 0.280 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2012 | 451 | 0.280 |
Why?
|
| Muscle, Smooth, Vascular | 3 | 2019 | 1504 | 0.280 |
Why?
|
| Taurine | 1 | 2006 | 94 | 0.280 |
Why?
|
| Mutation | 14 | 2021 | 29786 | 0.280 |
Why?
|
| Factor VII | 1 | 2006 | 139 | 0.280 |
Why?
|
| GABA Agonists | 1 | 2006 | 111 | 0.280 |
Why?
|
| Hematoma, Subdural, Intracranial | 2 | 2017 | 33 | 0.270 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2005 | 50 | 0.270 |
Why?
|
| Statistics as Topic | 3 | 2011 | 2373 | 0.270 |
Why?
|
| Cross-Sectional Studies | 18 | 2024 | 25039 | 0.270 |
Why?
|
| Intracranial Hemorrhage, Hypertensive | 2 | 2017 | 20 | 0.270 |
Why?
|
| Multivariate Analysis | 21 | 2020 | 12244 | 0.260 |
Why?
|
| Treatment Outcome | 29 | 2023 | 63107 | 0.260 |
Why?
|
| Statistics, Nonparametric | 9 | 2017 | 2887 | 0.260 |
Why?
|
| Deferoxamine | 2 | 2019 | 151 | 0.260 |
Why?
|
| Myositis, Inclusion Body | 1 | 2007 | 147 | 0.250 |
Why?
|
| Mental Recall | 1 | 2011 | 1206 | 0.250 |
Why?
|
| Fibrinolytic Agents | 4 | 2023 | 2158 | 0.250 |
Why?
|
| Alleles | 10 | 2013 | 6933 | 0.240 |
Why?
|
| Wakefulness | 2 | 2023 | 1245 | 0.240 |
Why?
|
| Nerve Net | 1 | 2016 | 2175 | 0.240 |
Why?
|
| Memory | 6 | 2016 | 2174 | 0.240 |
Why?
|
| Cognition | 10 | 2023 | 6770 | 0.240 |
Why?
|
| Interferon-beta | 3 | 2015 | 324 | 0.240 |
Why?
|
| Genetic Variation | 10 | 2015 | 6542 | 0.240 |
Why?
|
| Severity of Illness Index | 19 | 2021 | 15535 | 0.230 |
Why?
|
| Nicardipine | 2 | 2021 | 60 | 0.230 |
Why?
|
| Cerebral Ventricles | 2 | 2019 | 544 | 0.230 |
Why?
|
| Aging | 9 | 2023 | 8664 | 0.220 |
Why?
|
| Alzheimer Vaccines | 1 | 2003 | 25 | 0.220 |
Why?
|
| Megakaryocytes | 4 | 1992 | 545 | 0.220 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2023 | 68 | 0.220 |
Why?
|
| Vasculitis | 1 | 2007 | 519 | 0.220 |
Why?
|
| Urinary Tract Infections | 3 | 2018 | 788 | 0.220 |
Why?
|
| Administration, Oral | 5 | 2023 | 3914 | 0.220 |
Why?
|
| Radiography | 10 | 2016 | 7023 | 0.220 |
Why?
|
| Risk | 12 | 2019 | 9688 | 0.220 |
Why?
|
| Logistic Models | 17 | 2021 | 13409 | 0.210 |
Why?
|
| Calcinosis | 3 | 2021 | 1499 | 0.210 |
Why?
|
| Headache | 2 | 2007 | 1226 | 0.210 |
Why?
|
| Intermediate Filaments | 1 | 2023 | 175 | 0.210 |
Why?
|
| Education | 2 | 2020 | 543 | 0.210 |
Why?
|
| Apathy | 1 | 2023 | 96 | 0.210 |
Why?
|
| Iowa | 6 | 2010 | 101 | 0.210 |
Why?
|
| Ischemia | 3 | 2017 | 1907 | 0.210 |
Why?
|
| Myeloid Cells | 1 | 2007 | 810 | 0.200 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 3 | 2015 | 518 | 0.200 |
Why?
|
| Myocardial Infarction | 4 | 2022 | 11718 | 0.200 |
Why?
|
| Cholesterol | 3 | 2016 | 2919 | 0.200 |
Why?
|
| Brain Stem | 3 | 2017 | 846 | 0.200 |
Why?
|
| Diagnosis, Differential | 10 | 2016 | 12961 | 0.200 |
Why?
|
| Animals | 43 | 2024 | 168768 | 0.200 |
Why?
|
| Sensitivity and Specificity | 12 | 2023 | 14723 | 0.190 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2022 | 336 | 0.190 |
Why?
|
| Aplysia | 4 | 1987 | 41 | 0.190 |
Why?
|
| Follow-Up Studies | 21 | 2021 | 39052 | 0.190 |
Why?
|
| Radiopharmaceuticals | 2 | 2007 | 2645 | 0.190 |
Why?
|
| Apolipoproteins D | 1 | 2020 | 14 | 0.190 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2021 | 56 | 0.180 |
Why?
|
| Matrix Metalloproteinase 9 | 3 | 2015 | 638 | 0.180 |
Why?
|
| Double-Blind Method | 8 | 2019 | 12025 | 0.180 |
Why?
|
| Hemangioma, Cavernous | 1 | 2021 | 110 | 0.180 |
Why?
|
| Off-Label Use | 1 | 2021 | 169 | 0.180 |
Why?
|
| Polymorphism, Single Nucleotide | 15 | 2022 | 15520 | 0.180 |
Why?
|
| Brain Edema | 3 | 2017 | 617 | 0.180 |
Why?
|
| Iatrogenic Disease | 1 | 2023 | 547 | 0.180 |
Why?
|
| Signal Transduction | 3 | 2019 | 23404 | 0.180 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 2 | 2013 | 292 | 0.170 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 3 | 2010 | 257 | 0.170 |
Why?
|
| Genome-Wide Association Study | 13 | 2019 | 12262 | 0.170 |
Why?
|
| Indans | 1 | 2000 | 96 | 0.170 |
Why?
|
| Incidence | 11 | 2021 | 20952 | 0.170 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 4386 | 0.170 |
Why?
|
| Adult | 39 | 2024 | 214052 | 0.170 |
Why?
|
| Markov Chains | 5 | 2011 | 969 | 0.170 |
Why?
|
| Residence Characteristics | 3 | 2014 | 2050 | 0.160 |
Why?
|
| Tomography Scanners, X-Ray Computed | 2 | 2016 | 168 | 0.160 |
Why?
|
| Mice, Transgenic | 13 | 2023 | 9735 | 0.160 |
Why?
|
| Nootropic Agents | 1 | 2000 | 160 | 0.160 |
Why?
|
| Intracranial Embolism | 2 | 2018 | 202 | 0.160 |
Why?
|
| Ear | 1 | 2019 | 173 | 0.160 |
Why?
|
| Research Design | 3 | 2021 | 5984 | 0.160 |
Why?
|
| Iron Chelating Agents | 1 | 2019 | 139 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 4 | 2 | 2010 | 374 | 0.160 |
Why?
|
| Prevalence | 12 | 2021 | 15221 | 0.150 |
Why?
|
| Atrophy | 6 | 2020 | 1584 | 0.150 |
Why?
|
| Gene Frequency | 8 | 2011 | 3587 | 0.150 |
Why?
|
| Perioperative Period | 1 | 2019 | 256 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 1999 | 1284 | 0.150 |
Why?
|
| Seizures | 4 | 2016 | 2859 | 0.150 |
Why?
|
| Antidotes | 1 | 2018 | 138 | 0.150 |
Why?
|
| Secondary Prevention | 4 | 2015 | 1530 | 0.150 |
Why?
|
| Depression | 4 | 2022 | 7759 | 0.150 |
Why?
|
| Prehypertension | 1 | 2017 | 61 | 0.150 |
Why?
|
| Research | 3 | 2022 | 1999 | 0.150 |
Why?
|
| Chaplaincy Service, Hospital | 1 | 2017 | 22 | 0.150 |
Why?
|
| Pneumonia | 3 | 2018 | 2133 | 0.150 |
Why?
|
| Subarachnoid Space | 1 | 2017 | 79 | 0.150 |
Why?
|
| Temporal Lobe | 2 | 2017 | 1670 | 0.150 |
Why?
|
| United States | 20 | 2022 | 69872 | 0.150 |
Why?
|
| Mice | 23 | 2023 | 81201 | 0.150 |
Why?
|
| Acute Disease | 8 | 2019 | 7147 | 0.140 |
Why?
|
| Reproducibility of Results | 10 | 2023 | 19905 | 0.140 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 2 | 2007 | 105 | 0.140 |
Why?
|
| Arousal | 2 | 2013 | 1164 | 0.140 |
Why?
|
| Extracellular Fluid | 2 | 2019 | 167 | 0.140 |
Why?
|
| Protein Kinases | 4 | 1987 | 1640 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2018 | 437 | 0.140 |
Why?
|
| Analysis of Variance | 4 | 2014 | 6366 | 0.140 |
Why?
|
| Plasma | 2 | 2017 | 575 | 0.140 |
Why?
|
| Brain Mapping | 5 | 2015 | 6670 | 0.140 |
Why?
|
| Hypoalbuminemia | 1 | 2017 | 85 | 0.140 |
Why?
|
| Adjuvants, Immunologic | 2 | 2015 | 1000 | 0.140 |
Why?
|
| Models, Biological | 1 | 2012 | 9584 | 0.140 |
Why?
|
| Recombinant Proteins | 5 | 2018 | 6621 | 0.140 |
Why?
|
| Pastoral Care | 1 | 2017 | 73 | 0.140 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2010 | 3047 | 0.130 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2016 | 110 | 0.130 |
Why?
|
| Hypernatremia | 1 | 2016 | 82 | 0.130 |
Why?
|
| Ethylene Glycols | 1 | 2016 | 156 | 0.130 |
Why?
|
| Critical Care | 3 | 2017 | 2647 | 0.130 |
Why?
|
| Dendritic Cells | 1 | 2007 | 2725 | 0.130 |
Why?
|
| Neurosciences | 1 | 2020 | 348 | 0.130 |
Why?
|
| Arterioles | 2 | 2023 | 254 | 0.130 |
Why?
|
| Cardiovascular System | 1 | 2023 | 831 | 0.130 |
Why?
|
| Astrocytes | 4 | 2023 | 1273 | 0.130 |
Why?
|
| Purpura | 1 | 1996 | 122 | 0.130 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2016 | 138 | 0.130 |
Why?
|
| Mitogens | 1 | 1995 | 232 | 0.130 |
Why?
|
| Hypocalcemia | 1 | 2016 | 191 | 0.130 |
Why?
|
| Urine | 1 | 2017 | 370 | 0.130 |
Why?
|
| Pons | 1 | 2016 | 245 | 0.130 |
Why?
|
| Mutation, Missense | 2 | 2001 | 2566 | 0.130 |
Why?
|
| Perceptual Disorders | 1 | 2017 | 196 | 0.130 |
Why?
|
| Guidelines as Topic | 2 | 2019 | 1405 | 0.130 |
Why?
|
| Sputum | 1 | 2017 | 476 | 0.120 |
Why?
|
| Lymphopenia | 1 | 2017 | 285 | 0.120 |
Why?
|
| Atrial Flutter | 1 | 2017 | 263 | 0.120 |
Why?
|
| Neurons, Afferent | 2 | 1987 | 506 | 0.120 |
Why?
|
| Quality-Adjusted Life Years | 4 | 2011 | 1683 | 0.120 |
Why?
|
| Longevity | 1 | 2022 | 1071 | 0.120 |
Why?
|
| Blood | 1 | 2017 | 598 | 0.120 |
Why?
|
| Iron | 2 | 2023 | 1774 | 0.120 |
Why?
|
| Chi-Square Distribution | 3 | 2017 | 3508 | 0.120 |
Why?
|
| Peroxidase | 1 | 2017 | 611 | 0.120 |
Why?
|
| Genes, Dominant | 3 | 2021 | 880 | 0.120 |
Why?
|
| Gliosis | 2 | 2023 | 245 | 0.120 |
Why?
|
| Odds Ratio | 11 | 2019 | 9849 | 0.120 |
Why?
|
| DNA Mutational Analysis | 5 | 2019 | 4185 | 0.120 |
Why?
|
| Homocysteine | 2 | 2009 | 647 | 0.120 |
Why?
|
| Serum Albumin | 1 | 2017 | 675 | 0.120 |
Why?
|
| Congenital Abnormalities | 1 | 2019 | 707 | 0.120 |
Why?
|
| Boston | 5 | 2018 | 9312 | 0.120 |
Why?
|
| Area Under Curve | 2 | 2009 | 1655 | 0.120 |
Why?
|
| Coma, Post-Head Injury | 1 | 2013 | 21 | 0.110 |
Why?
|
| Fluorine Radioisotopes | 1 | 2016 | 442 | 0.110 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 1584 | 0.110 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 2007 | 845 | 0.110 |
Why?
|
| Sepsis | 2 | 2018 | 2593 | 0.110 |
Why?
|
| Proportional Hazards Models | 9 | 2017 | 12356 | 0.110 |
Why?
|
| Unnecessary Procedures | 1 | 2017 | 432 | 0.110 |
Why?
|
| Cyclic AMP | 2 | 1987 | 1472 | 0.110 |
Why?
|
| Hospital Mortality | 7 | 2016 | 5316 | 0.110 |
Why?
|
| Fatal Outcome | 3 | 2013 | 1851 | 0.110 |
Why?
|
| Risk Assessment | 10 | 2020 | 23336 | 0.110 |
Why?
|
| Glasgow Coma Scale | 4 | 2017 | 570 | 0.110 |
Why?
|
| Ciliary Neurotrophic Factor Receptor alpha Subunit | 1 | 2012 | 4 | 0.110 |
Why?
|
| Asymptomatic Diseases | 3 | 2021 | 551 | 0.110 |
Why?
|
| Cyclooxygenase 2 | 1 | 2015 | 612 | 0.110 |
Why?
|
| Blood-Brain Barrier | 1 | 2019 | 1019 | 0.110 |
Why?
|
| Health Personnel | 2 | 2016 | 3219 | 0.110 |
Why?
|
| Ventilator-Induced Lung Injury | 1 | 2013 | 122 | 0.100 |
Why?
|
| Leukocyte Count | 1 | 2016 | 1588 | 0.100 |
Why?
|
| Phosphorylation | 6 | 2013 | 8436 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 1 | 2000 | 2007 | 0.100 |
Why?
|
| Age Factors | 11 | 2017 | 18373 | 0.100 |
Why?
|
| Neurology | 1 | 2020 | 763 | 0.100 |
Why?
|
| Disease Models, Animal | 10 | 2023 | 18034 | 0.100 |
Why?
|
| Patient Selection | 3 | 2021 | 4216 | 0.100 |
Why?
|
| Brain Injuries | 2 | 2016 | 2029 | 0.100 |
Why?
|
| Continuity of Patient Care | 1 | 2019 | 1049 | 0.100 |
Why?
|
| Receptors, Complement 3b | 1 | 2012 | 145 | 0.100 |
Why?
|
| Family Health | 1 | 2017 | 1281 | 0.100 |
Why?
|
| Acute Lung Injury | 2 | 2013 | 380 | 0.100 |
Why?
|
| Taiwan | 1 | 2013 | 496 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2014 | 658 | 0.100 |
Why?
|
| Amino Acid Sequence | 8 | 2012 | 13814 | 0.100 |
Why?
|
| Time Factors | 13 | 2021 | 40075 | 0.100 |
Why?
|
| Cladribine | 1 | 2011 | 34 | 0.100 |
Why?
|
| Muscle, Skeletal | 1 | 2007 | 4925 | 0.100 |
Why?
|
| Piperidines | 1 | 2000 | 1602 | 0.100 |
Why?
|
| Blood Coagulation | 3 | 2012 | 1127 | 0.100 |
Why?
|
| Mental Disorders | 2 | 2011 | 6598 | 0.100 |
Why?
|
| Neurons | 5 | 2011 | 9340 | 0.100 |
Why?
|
| Tidal Volume | 1 | 2013 | 490 | 0.100 |
Why?
|
| Sex Characteristics | 2 | 2023 | 2585 | 0.100 |
Why?
|
| Cytoskeleton | 2 | 1996 | 1185 | 0.100 |
Why?
|
| Bleomycin | 1 | 2012 | 512 | 0.100 |
Why?
|
| Transforming Growth Factors | 1 | 1990 | 76 | 0.090 |
Why?
|
| Postoperative Hemorrhage | 1 | 2014 | 412 | 0.090 |
Why?
|
| Oxidative Phosphorylation | 1 | 2013 | 481 | 0.090 |
Why?
|
| Genes, Mitochondrial | 1 | 2010 | 61 | 0.090 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 2 | 2015 | 271 | 0.090 |
Why?
|
| Principal Component Analysis | 2 | 2010 | 940 | 0.090 |
Why?
|
| Tomography, Spiral Computed | 1 | 2012 | 280 | 0.090 |
Why?
|
| Blood Loss, Surgical | 1 | 2014 | 662 | 0.090 |
Why?
|
| Erythrocyte Transfusion | 2 | 2013 | 565 | 0.090 |
Why?
|
| Calcium | 4 | 2023 | 5755 | 0.090 |
Why?
|
| Genetic Testing | 3 | 2019 | 3444 | 0.090 |
Why?
|
| Molecular Sequence Data | 8 | 2012 | 18111 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2011 | 3873 | 0.090 |
Why?
|
| Immunologic Factors | 1 | 2019 | 1580 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2015 | 10943 | 0.090 |
Why?
|
| Macrophages, Alveolar | 1 | 2012 | 407 | 0.090 |
Why?
|
| Defibrillators, Implantable | 3 | 2007 | 1440 | 0.090 |
Why?
|
| Genes | 2 | 2013 | 1893 | 0.090 |
Why?
|
| Photic Stimulation | 3 | 2023 | 2026 | 0.080 |
Why?
|
| Positive-Pressure Respiration | 1 | 2013 | 633 | 0.080 |
Why?
|
| Pulmonary Alveoli | 1 | 2012 | 675 | 0.080 |
Why?
|
| Delayed Diagnosis | 1 | 2012 | 441 | 0.080 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 1988 | 48 | 0.080 |
Why?
|
| Pedigree | 3 | 2021 | 4642 | 0.080 |
Why?
|
| Gyrus Cinguli | 1 | 2015 | 1091 | 0.080 |
Why?
|
| Cyclophosphamide | 2 | 2005 | 2242 | 0.080 |
Why?
|
| Genetic Association Studies | 3 | 2015 | 2703 | 0.080 |
Why?
|
| Biopsy | 4 | 2016 | 6755 | 0.080 |
Why?
|
| Regression Analysis | 4 | 2016 | 6459 | 0.080 |
Why?
|
| Health Status | 1 | 2022 | 4034 | 0.080 |
Why?
|
| DNA | 4 | 2019 | 7294 | 0.080 |
Why?
|
| Triglycerides | 1 | 2016 | 2453 | 0.080 |
Why?
|
| Visual Perception | 1 | 2017 | 1420 | 0.080 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 2031 | 0.080 |
Why?
|
| Hematoma, Subdural | 1 | 2009 | 126 | 0.080 |
Why?
|
| Consciousness Disorders | 1 | 2012 | 418 | 0.080 |
Why?
|
| Anesthesia | 1 | 2019 | 1561 | 0.080 |
Why?
|
| Spirometry | 1 | 2010 | 865 | 0.080 |
Why?
|
| Connective Tissue | 1 | 2009 | 420 | 0.080 |
Why?
|
| Functional Laterality | 1 | 2014 | 2290 | 0.080 |
Why?
|
| Mixed Function Oxygenases | 1 | 2009 | 272 | 0.080 |
Why?
|
| Drainage | 1 | 2013 | 1142 | 0.080 |
Why?
|
| Immunoglobulin G | 2 | 2019 | 4561 | 0.080 |
Why?
|
| Rats | 5 | 2022 | 24252 | 0.080 |
Why?
|
| Enzyme Activation | 5 | 1999 | 3702 | 0.070 |
Why?
|
| Probability | 1 | 2013 | 2506 | 0.070 |
Why?
|
| Cyclic AMP Receptor Protein | 1 | 1987 | 23 | 0.070 |
Why?
|
| Drug Interactions | 1 | 2012 | 1460 | 0.070 |
Why?
|
| Primary Prevention | 1 | 2014 | 1167 | 0.070 |
Why?
|
| Base Sequence | 6 | 2011 | 12797 | 0.070 |
Why?
|
| Dipeptides | 1 | 2009 | 409 | 0.070 |
Why?
|
| Glial Fibrillary Acidic Protein | 2 | 2020 | 529 | 0.070 |
Why?
|
| von Willebrand Factor | 1 | 1991 | 669 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2017 | 6539 | 0.070 |
Why?
|
| Consciousness | 1 | 2012 | 572 | 0.070 |
Why?
|
| Age of Onset | 3 | 2003 | 3270 | 0.070 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2020 | 314 | 0.070 |
Why?
|
| Immunotherapy | 2 | 2019 | 4446 | 0.070 |
Why?
|
| Capillary Permeability | 2 | 2021 | 798 | 0.070 |
Why?
|
| Erythropoietin | 1 | 1991 | 726 | 0.070 |
Why?
|
| Models, Neurological | 1 | 2014 | 1775 | 0.070 |
Why?
|
| Immunohistochemistry | 5 | 2010 | 11366 | 0.070 |
Why?
|
| Interleukins | 1 | 1991 | 791 | 0.070 |
Why?
|
| Smoking | 2 | 2022 | 8987 | 0.070 |
Why?
|
| Disability Evaluation | 2 | 2017 | 1828 | 0.070 |
Why?
|
| Cardiac Output, Low | 1 | 2007 | 195 | 0.070 |
Why?
|
| Placebos | 1 | 2010 | 1676 | 0.070 |
Why?
|
| Factor VIIa | 1 | 2006 | 101 | 0.070 |
Why?
|
| GTP-Binding Proteins | 3 | 2007 | 970 | 0.070 |
Why?
|
| Hong Kong | 2 | 2021 | 148 | 0.070 |
Why?
|
| Basal Ganglia | 2 | 2023 | 546 | 0.070 |
Why?
|
| Models, Cardiovascular | 1 | 2011 | 996 | 0.070 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2005 | 20 | 0.070 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2005 | 42 | 0.070 |
Why?
|
| Patient Transfer | 1 | 2012 | 762 | 0.070 |
Why?
|
| Forced Expiratory Volume | 1 | 2010 | 1745 | 0.070 |
Why?
|
| Half-Life | 1 | 2006 | 661 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2022 | 13035 | 0.070 |
Why?
|
| Comorbidity | 5 | 2020 | 10388 | 0.060 |
Why?
|
| Survival Analysis | 5 | 2021 | 10252 | 0.060 |
Why?
|
| ROC Curve | 2 | 2012 | 3528 | 0.060 |
Why?
|
| Thromboembolism | 2 | 2008 | 987 | 0.060 |
Why?
|
| Basement Membrane | 1 | 2006 | 357 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 791 | 0.060 |
Why?
|
| Mitosis | 1 | 1990 | 1208 | 0.060 |
Why?
|
| Genetics, Population | 1 | 2010 | 934 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2010 | 4933 | 0.060 |
Why?
|
| DNA, Mitochondrial | 1 | 2010 | 817 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1994 | 2455 | 0.060 |
Why?
|
| Inflammation Mediators | 2 | 2021 | 1888 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2012 | 4222 | 0.060 |
Why?
|
| Ticlopidine | 1 | 2010 | 899 | 0.060 |
Why?
|
| PC12 Cells | 2 | 1995 | 331 | 0.060 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2007 | 271 | 0.060 |
Why?
|
| Lewy Body Disease | 1 | 2007 | 229 | 0.060 |
Why?
|
| Autoantibodies | 1 | 2013 | 2036 | 0.060 |
Why?
|
| Blood Flow Velocity | 1 | 2008 | 1423 | 0.060 |
Why?
|
| Prefrontal Cortex | 1 | 2015 | 2147 | 0.060 |
Why?
|
| Organ Size | 3 | 2017 | 2251 | 0.060 |
Why?
|
| Immunization, Passive | 1 | 2007 | 623 | 0.060 |
Why?
|
| Length of Stay | 3 | 2012 | 6311 | 0.060 |
Why?
|
| Dexamethasone | 1 | 2011 | 1951 | 0.060 |
Why?
|
| Linkage Disequilibrium | 2 | 2008 | 1997 | 0.060 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2014 | 1433 | 0.060 |
Why?
|
| Sex Factors | 5 | 2018 | 10400 | 0.060 |
Why?
|
| Electrocardiography | 3 | 2017 | 6442 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 4 | 2010 | 6171 | 0.060 |
Why?
|
| Critical Illness | 1 | 2017 | 2670 | 0.060 |
Why?
|
| Sleep | 1 | 2020 | 4622 | 0.060 |
Why?
|
| Recovery of Function | 2 | 2018 | 2926 | 0.060 |
Why?
|
| CHO Cells | 3 | 1995 | 1409 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 625 | 0.060 |
Why?
|
| Down-Regulation | 4 | 2009 | 3001 | 0.060 |
Why?
|
| Capillaries | 2 | 2019 | 773 | 0.060 |
Why?
|
| Neurologic Examination | 1 | 2007 | 931 | 0.060 |
Why?
|
| Lectins, C-Type | 1 | 2007 | 589 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2014 | 3326 | 0.060 |
Why?
|
| Carotid Artery, External | 1 | 2003 | 38 | 0.060 |
Why?
|
| Collagen | 1 | 2012 | 2688 | 0.060 |
Why?
|
| Plasma Cells | 1 | 2007 | 591 | 0.060 |
Why?
|
| Survival Rate | 5 | 2021 | 12788 | 0.060 |
Why?
|
| Anemia | 2 | 2011 | 1503 | 0.060 |
Why?
|
| Electric Countershock | 1 | 2006 | 534 | 0.060 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2006 | 560 | 0.060 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2023 | 61 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2012 | 8300 | 0.060 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2007 | 4042 | 0.050 |
Why?
|
| Vitamins | 2 | 2009 | 1623 | 0.050 |
Why?
|
| Vasodilation | 2 | 2023 | 944 | 0.050 |
Why?
|
| Cricetinae | 3 | 1995 | 2475 | 0.050 |
Why?
|
| Anticonvulsants | 1 | 2012 | 1916 | 0.050 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2008 | 1107 | 0.050 |
Why?
|
| Linear Models | 3 | 2019 | 5953 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2023 | 149 | 0.050 |
Why?
|
| Netherlands | 2 | 2018 | 2170 | 0.050 |
Why?
|
| Myocardial Ischemia | 2 | 2011 | 2148 | 0.050 |
Why?
|
| Interferon-alpha | 1 | 2007 | 895 | 0.050 |
Why?
|
| Kentucky | 1 | 2002 | 83 | 0.050 |
Why?
|
| Survivors | 3 | 2015 | 2291 | 0.050 |
Why?
|
| Congresses as Topic | 2 | 2019 | 764 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3135 | 0.050 |
Why?
|
| Antigens, Surface | 1 | 2007 | 1663 | 0.050 |
Why?
|
| Activities of Daily Living | 3 | 2023 | 2419 | 0.050 |
Why?
|
| Intracranial Thrombosis | 1 | 2003 | 113 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3242 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2011 | 2108 | 0.050 |
Why?
|
| Glucose-6-Phosphate Isomerase | 1 | 2021 | 52 | 0.050 |
Why?
|
| Amyloid Neuropathies | 1 | 2001 | 15 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2010 | 1988 | 0.050 |
Why?
|
| Spain | 1 | 2003 | 465 | 0.050 |
Why?
|
| Forecasting | 1 | 2011 | 2951 | 0.050 |
Why?
|
| Ohio | 1 | 2002 | 337 | 0.050 |
Why?
|
| Spermidine | 1 | 2021 | 56 | 0.050 |
Why?
|
| Codon | 1 | 2003 | 611 | 0.050 |
Why?
|
| Single-Blind Method | 2 | 2015 | 1590 | 0.050 |
Why?
|
| Amino Acid Substitution | 2 | 2003 | 1793 | 0.050 |
Why?
|
| Antibodies | 2 | 2007 | 2460 | 0.050 |
Why?
|
| Antigen Presentation | 1 | 2007 | 1284 | 0.050 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2021 | 187 | 0.050 |
Why?
|
| Myocardial Contraction | 1 | 2006 | 1579 | 0.050 |
Why?
|
| Thrombolytic Therapy | 2 | 2022 | 2162 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2019 | 2274 | 0.050 |
Why?
|
| Phagocytosis | 1 | 2006 | 1539 | 0.050 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2023 | 472 | 0.050 |
Why?
|
| Dilatation | 1 | 2021 | 291 | 0.050 |
Why?
|
| Neoplastic Stem Cells | 1 | 1988 | 1376 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2007 | 1423 | 0.050 |
Why?
|
| Rodentia | 1 | 2022 | 261 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2007 | 1783 | 0.050 |
Why?
|
| Polymorphism, Genetic | 4 | 1999 | 4328 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 3 | 1999 | 489 | 0.040 |
Why?
|
| Antidepressive Agents | 2 | 2022 | 2838 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2012 | 3690 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 8861 | 0.040 |
Why?
|
| Data Collection | 1 | 2009 | 3339 | 0.040 |
Why?
|
| Aspirin | 3 | 2013 | 3283 | 0.040 |
Why?
|
| Cross-Over Studies | 2 | 2007 | 2029 | 0.040 |
Why?
|
| Causality | 2 | 2005 | 1275 | 0.040 |
Why?
|
| Apolipoprotein E3 | 1 | 2019 | 97 | 0.040 |
Why?
|
| Introns | 2 | 1999 | 992 | 0.040 |
Why?
|
| Yersinia pseudotuberculosis | 1 | 1999 | 27 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2011 | 3743 | 0.040 |
Why?
|
| Vasomotor System | 1 | 2019 | 209 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2006 | 1525 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2012 | 6194 | 0.040 |
Why?
|
| Germany | 1 | 2001 | 862 | 0.040 |
Why?
|
| alpha-Macroglobulins | 1 | 1998 | 64 | 0.040 |
Why?
|
| Osmolar Concentration | 2 | 2009 | 683 | 0.040 |
Why?
|
| Reference Values | 2 | 2000 | 4982 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2008 | 2355 | 0.040 |
Why?
|
| Exudates and Transudates | 1 | 2019 | 172 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2011 | 3589 | 0.040 |
Why?
|
| Nerve Growth Factors | 1 | 2021 | 574 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 5 | 2019 | 21833 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 1999 | 480 | 0.040 |
Why?
|
| Type C Phospholipases | 1 | 1998 | 292 | 0.040 |
Why?
|
| Benzene Derivatives | 2 | 2009 | 54 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2009 | 3084 | 0.040 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2023 | 857 | 0.040 |
Why?
|
| Medical Futility | 1 | 2019 | 127 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2007 | 2504 | 0.040 |
Why?
|
| Alkenes | 2 | 2009 | 57 | 0.040 |
Why?
|
| Oxygen | 2 | 2022 | 4189 | 0.040 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2007 | 2269 | 0.040 |
Why?
|
| Stem Cells | 1 | 1991 | 3567 | 0.040 |
Why?
|
| PubMed | 1 | 2018 | 123 | 0.040 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1998 | 429 | 0.040 |
Why?
|
| Cost of Illness | 2 | 2017 | 1860 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2007 | 10183 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2007 | 1790 | 0.040 |
Why?
|
| Factor Xa | 1 | 2018 | 162 | 0.040 |
Why?
|
| Heart Atria | 1 | 2023 | 1356 | 0.040 |
Why?
|
| Early Diagnosis | 2 | 2016 | 1184 | 0.040 |
Why?
|
| Massachusetts | 3 | 2020 | 8662 | 0.040 |
Why?
|
| Gene Expression | 2 | 2021 | 7798 | 0.040 |
Why?
|
| Epilepsy | 1 | 2012 | 3310 | 0.040 |
Why?
|
| Receptors, Cyclic AMP | 2 | 1987 | 20 | 0.040 |
Why?
|
| Presenilin-1 | 2 | 2011 | 635 | 0.040 |
Why?
|
| Patient Admission | 2 | 2017 | 1380 | 0.040 |
Why?
|
| Intensive Care Units | 3 | 2017 | 3680 | 0.040 |
Why?
|
| Observer Variation | 2 | 2017 | 2593 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 7182 | 0.040 |
Why?
|
| Stilbenes | 2 | 2009 | 155 | 0.040 |
Why?
|
| Nonlinear Dynamics | 1 | 2019 | 502 | 0.040 |
Why?
|
| Thalamus | 2 | 2013 | 1023 | 0.040 |
Why?
|
| Young Adult | 6 | 2019 | 56429 | 0.040 |
Why?
|
| Decision Making | 1 | 2010 | 3888 | 0.040 |
Why?
|
| Blood Component Transfusion | 1 | 2017 | 143 | 0.040 |
Why?
|
| Acute Kidney Injury | 1 | 2009 | 1968 | 0.040 |
Why?
|
| Fibrin | 1 | 2019 | 506 | 0.030 |
Why?
|
| Emergency Service, Hospital | 2 | 2012 | 7658 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2019 | 779 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 1677 | 0.030 |
Why?
|
| Databases, Factual | 3 | 2017 | 7730 | 0.030 |
Why?
|
| Alkylation | 1 | 1995 | 86 | 0.030 |
Why?
|
| Cricetulus | 2 | 1995 | 818 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 9445 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2007 | 3771 | 0.030 |
Why?
|
| Telemetry | 1 | 2017 | 207 | 0.030 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2016 | 82 | 0.030 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1998 | 548 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2019 | 574 | 0.030 |
Why?
|
| Community Health Planning | 1 | 2016 | 165 | 0.030 |
Why?
|
| Lipoproteins, VLDL | 1 | 1996 | 201 | 0.030 |
Why?
|
| Adolescent | 7 | 2019 | 85779 | 0.030 |
Why?
|
| Spin Labels | 1 | 2016 | 332 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2012 | 2971 | 0.030 |
Why?
|
| Trinucleotide Repeats | 1 | 1996 | 261 | 0.030 |
Why?
|
| GTP Phosphohydrolases | 1 | 1998 | 508 | 0.030 |
Why?
|
| Angiography | 1 | 2021 | 1639 | 0.030 |
Why?
|
| Platelet Factor 4 | 1 | 1995 | 129 | 0.030 |
Why?
|
| Iodine | 1 | 2017 | 286 | 0.030 |
Why?
|
| Nurses | 1 | 2005 | 2462 | 0.030 |
Why?
|
| Vitamin K | 1 | 2017 | 295 | 0.030 |
Why?
|
| Leukocytosis | 1 | 2016 | 247 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2004 | 1856 | 0.030 |
Why?
|
| Calibration | 1 | 2017 | 816 | 0.030 |
Why?
|
| Antifibrinolytic Agents | 1 | 2017 | 254 | 0.030 |
Why?
|
| Cell Line | 5 | 1998 | 16000 | 0.030 |
Why?
|
| Random Allocation | 1 | 2019 | 2428 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2005 | 6036 | 0.030 |
Why?
|
| Societies | 1 | 2014 | 104 | 0.030 |
Why?
|
| Arginine | 1 | 2018 | 944 | 0.030 |
Why?
|
| Vitamin B 12 | 2 | 2009 | 527 | 0.030 |
Why?
|
| Reaction Time | 1 | 2021 | 2098 | 0.030 |
Why?
|
| Heparitin Sulfate | 1 | 1995 | 225 | 0.030 |
Why?
|
| Echocardiography | 1 | 2007 | 5099 | 0.030 |
Why?
|
| Hippocampus | 2 | 2023 | 3675 | 0.030 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 1996 | 365 | 0.030 |
Why?
|
| Blood Proteins | 1 | 2019 | 1124 | 0.030 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2017 | 475 | 0.030 |
Why?
|
| Isoenzymes | 1 | 1998 | 1728 | 0.030 |
Why?
|
| Macrophages | 2 | 2006 | 5660 | 0.030 |
Why?
|
| Chemokines, CXC | 1 | 1995 | 422 | 0.030 |
Why?
|
| Disulfides | 1 | 1995 | 457 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2011 | 12721 | 0.030 |
Why?
|
| Reference Standards | 1 | 1997 | 1025 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2021 | 2204 | 0.030 |
Why?
|
| Coronary Disease | 1 | 2008 | 6077 | 0.030 |
Why?
|
| Microglia | 1 | 2021 | 1267 | 0.030 |
Why?
|
| Thrombectomy | 1 | 2018 | 680 | 0.030 |
Why?
|
| Genetic Markers | 2 | 2010 | 2634 | 0.030 |
Why?
|
| Heart Failure | 2 | 2007 | 10895 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2018 | 921 | 0.030 |
Why?
|
| Hospitals, General | 1 | 2017 | 749 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2021 | 1901 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2021 | 1099 | 0.030 |
Why?
|
| Haplotypes | 2 | 2010 | 2779 | 0.030 |
Why?
|
| Dinoprostone | 1 | 2015 | 601 | 0.030 |
Why?
|
| Cells, Cultured | 4 | 2006 | 19233 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2009 | 2618 | 0.030 |
Why?
|
| Water-Electrolyte Balance | 1 | 2013 | 346 | 0.030 |
Why?
|
| Metabolomics | 1 | 2021 | 1485 | 0.030 |
Why?
|
| Goals | 1 | 2017 | 707 | 0.030 |
Why?
|
| Neuroanatomy | 1 | 2012 | 66 | 0.030 |
Why?
|
| Receptors, Chemokine | 1 | 1995 | 670 | 0.030 |
Why?
|
| Insulysin | 1 | 2011 | 50 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 1998 | 1970 | 0.030 |
Why?
|
| Creatinine | 2 | 2009 | 1919 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 2 | 2012 | 2716 | 0.030 |
Why?
|
| Patient Discharge | 2 | 2016 | 3318 | 0.030 |
Why?
|
| Kinetics | 3 | 2006 | 6476 | 0.030 |
Why?
|
| Electroencephalography | 1 | 2007 | 6151 | 0.030 |
Why?
|
| Lung | 1 | 2010 | 9857 | 0.030 |
Why?
|
| Blood Pressure Determination | 1 | 2015 | 633 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2005 | 5984 | 0.020 |
Why?
|
| Visual Cortex | 1 | 2019 | 1149 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 1992 | 821 | 0.020 |
Why?
|
| Arachidonate 12-Lipoxygenase | 1 | 1992 | 80 | 0.020 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 1992 | 226 | 0.020 |
Why?
|
| Greece | 1 | 2011 | 344 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2011 | 321 | 0.020 |
Why?
|
| Solubility | 1 | 2012 | 1088 | 0.020 |
Why?
|
| Registries | 2 | 2017 | 8091 | 0.020 |
Why?
|
| Vascular System Injuries | 1 | 2014 | 250 | 0.020 |
Why?
|
| Hospital Charges | 1 | 2012 | 362 | 0.020 |
Why?
|
| Evidence-Based Medicine | 2 | 2014 | 3611 | 0.020 |
Why?
|
| Folic Acid | 2 | 2009 | 1300 | 0.020 |
Why?
|
| Dissection | 1 | 2012 | 295 | 0.020 |
Why?
|
| Leukotrienes | 1 | 1992 | 255 | 0.020 |
Why?
|
| Pyramidal Tracts | 1 | 2012 | 256 | 0.020 |
Why?
|
| Lipoproteins | 1 | 2015 | 878 | 0.020 |
Why?
|
| Prosencephalon | 1 | 2012 | 303 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2015 | 1081 | 0.020 |
Why?
|
| Apoptosis | 1 | 2006 | 9724 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2016 | 1813 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 1995 | 2184 | 0.020 |
Why?
|
| Consensus | 1 | 2019 | 2960 | 0.020 |
Why?
|
| Vasoconstrictor Agents | 1 | 2013 | 642 | 0.020 |
Why?
|
| Software | 2 | 2017 | 4441 | 0.020 |
Why?
|
| Unfolded Protein Response | 1 | 2011 | 234 | 0.020 |
Why?
|
| Interleukin-3 | 1 | 1991 | 444 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2012 | 5181 | 0.020 |
Why?
|
| Hematocrit | 1 | 2011 | 636 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2015 | 1152 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 1375 | 0.020 |
Why?
|
| Fluorescent Dyes | 2 | 2009 | 1917 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2020 | 4196 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2022 | 3486 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 3 | 2015 | 4463 | 0.020 |
Why?
|
| Cyclic N-Oxides | 1 | 2009 | 78 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2017 | 8319 | 0.020 |
Why?
|
| Subdural Space | 1 | 2009 | 32 | 0.020 |
Why?
|
| Population Groups | 1 | 2010 | 209 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2017 | 2480 | 0.020 |
Why?
|
| Models, Genetic | 2 | 2010 | 3493 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 2 | 2010 | 3848 | 0.020 |
Why?
|
| Neprilysin | 1 | 2011 | 439 | 0.020 |
Why?
|
| Pyridoxine | 1 | 2009 | 102 | 0.020 |
Why?
|
| Surface Plasmon Resonance | 1 | 2009 | 274 | 0.020 |
Why?
|
| Epitope Mapping | 1 | 2009 | 311 | 0.020 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2009 | 421 | 0.020 |
Why?
|
| Ploidies | 1 | 1988 | 281 | 0.020 |
Why?
|
| Tomography, Optical Coherence | 1 | 2021 | 2657 | 0.020 |
Why?
|
| Peptide Library | 1 | 2009 | 349 | 0.020 |
Why?
|
| Mortality | 1 | 2020 | 2864 | 0.020 |
Why?
|
| Neurotransmitter Agents | 1 | 2012 | 647 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2018 | 3420 | 0.020 |
Why?
|
| Remission Induction | 1 | 2014 | 2385 | 0.020 |
Why?
|
| rac GTP-Binding Proteins | 2 | 1999 | 164 | 0.020 |
Why?
|
| Cadaver | 1 | 2012 | 1337 | 0.020 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2013 | 612 | 0.020 |
Why?
|
| Glasgow Outcome Scale | 1 | 2008 | 109 | 0.020 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 1988 | 293 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 1998 | 2917 | 0.020 |
Why?
|
| Steroids | 1 | 2013 | 930 | 0.020 |
Why?
|
| Neurofibrillary Tangles | 2 | 2001 | 439 | 0.020 |
Why?
|
| Piperazines | 1 | 2018 | 2488 | 0.020 |
Why?
|
| CADASIL | 1 | 2008 | 84 | 0.020 |
Why?
|
| Iceland | 1 | 2007 | 183 | 0.020 |
Why?
|
| Cross-Cultural Comparison | 1 | 2010 | 651 | 0.020 |
Why?
|
| Cell Division | 2 | 1995 | 4569 | 0.020 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2007 | 242 | 0.020 |
Why?
|
| Mice, Neurologic Mutants | 1 | 2006 | 126 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 1994 | 1692 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 1999 | 452 | 0.020 |
Why?
|
| Nerve Tissue | 1 | 1987 | 79 | 0.020 |
Why?
|
| Troponin I | 1 | 2011 | 619 | 0.020 |
Why?
|
| International Cooperation | 1 | 2013 | 1420 | 0.020 |
Why?
|
| Vibrissae | 1 | 2007 | 126 | 0.020 |
Why?
|
| Karyotyping | 1 | 1988 | 1243 | 0.020 |
Why?
|
| Matrix Metalloproteinases | 1 | 2009 | 391 | 0.020 |
Why?
|
| Vitamin B Complex | 1 | 2009 | 288 | 0.020 |
Why?
|
| Hypothalamus | 1 | 2012 | 1063 | 0.020 |
Why?
|
| Skin Window Technique | 1 | 2006 | 22 | 0.020 |
Why?
|
| Monocytes | 1 | 2016 | 2596 | 0.020 |
Why?
|
| Phenotype | 2 | 2015 | 16367 | 0.020 |
Why?
|
| Complement C1q | 1 | 2006 | 92 | 0.020 |
Why?
|
| Simvastatin | 1 | 2009 | 360 | 0.020 |
Why?
|
| Ginkgo biloba | 1 | 2006 | 26 | 0.020 |
Why?
|
| Calmodulin | 1 | 1987 | 209 | 0.020 |
Why?
|
| eIF-2 Kinase | 1 | 1987 | 150 | 0.020 |
Why?
|
| Hyperemia | 1 | 2007 | 225 | 0.020 |
Why?
|
| Troponin T | 1 | 2011 | 754 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2013 | 1547 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2014 | 2019 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2010 | 1252 | 0.020 |
Why?
|
| DNA Primers | 2 | 2001 | 2891 | 0.020 |
Why?
|
| Thrombophilia | 1 | 2008 | 305 | 0.020 |
Why?
|
| Hypercapnia | 1 | 2007 | 260 | 0.020 |
Why?
|
| Intracellular Membranes | 1 | 1987 | 391 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2010 | 1342 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 1995 | 2865 | 0.020 |
Why?
|
| Physical Stimulation | 1 | 2007 | 525 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 1988 | 927 | 0.020 |
Why?
|
| Health Policy | 1 | 2018 | 2661 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 1999 | 697 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 1999 | 3854 | 0.020 |
Why?
|
| Hypotension | 1 | 2011 | 884 | 0.020 |
Why?
|
| Levodopa | 1 | 2005 | 219 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2019 | 3116 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2019 | 41005 | 0.020 |
Why?
|
| rho-Associated Kinases | 1 | 2006 | 279 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2012 | 1184 | 0.020 |
Why?
|
| Contrast Media | 2 | 2009 | 5300 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2005 | 6489 | 0.020 |
Why?
|
| Exons | 1 | 2010 | 2439 | 0.020 |
Why?
|
| Life Tables | 1 | 2004 | 370 | 0.020 |
Why?
|
| Vasoconstriction | 1 | 2007 | 597 | 0.020 |
Why?
|
| Disease Management | 1 | 2015 | 2460 | 0.020 |
Why?
|
| Sweden | 1 | 2007 | 1341 | 0.020 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2006 | 238 | 0.010 |
Why?
|
| Cell Differentiation | 3 | 1992 | 11486 | 0.010 |
Why?
|
| Receptors, LDL | 1 | 2006 | 476 | 0.010 |
Why?
|
| Tubulin | 1 | 1987 | 695 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 2725 | 0.010 |
Why?
|
| Phytotherapy | 1 | 2006 | 298 | 0.010 |
Why?
|
| Peptide Hydrolases | 1 | 1987 | 634 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2019 | 4369 | 0.010 |
Why?
|
| Diagnostic Imaging | 2 | 2010 | 3508 | 0.010 |
Why?
|
| Neutrophils | 1 | 2016 | 3721 | 0.010 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2006 | 585 | 0.010 |
Why?
|
| Europe | 1 | 2010 | 3338 | 0.010 |
Why?
|
| Isoaspartic Acid | 1 | 2002 | 2 | 0.010 |
Why?
|
| Caregivers | 1 | 2015 | 2095 | 0.010 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2006 | 449 | 0.010 |
Why?
|
| Cell Membrane | 2 | 2006 | 3749 | 0.010 |
Why?
|
| Phospholipids | 1 | 1987 | 784 | 0.010 |
Why?
|
| Epitopes | 1 | 2009 | 2571 | 0.010 |
Why?
|
| Arteries | 1 | 2008 | 1119 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2006 | 880 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 1995 | 4459 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2006 | 2327 | 0.010 |
Why?
|
| Plant Extracts | 1 | 2006 | 471 | 0.010 |
Why?
|
| Serotonin | 1 | 1987 | 1017 | 0.010 |
Why?
|
| Skull | 1 | 2007 | 814 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2010 | 4740 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2006 | 1730 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2009 | 2076 | 0.010 |
Why?
|
| Exercise Tolerance | 1 | 2006 | 768 | 0.010 |
Why?
|
| Craniotomy | 1 | 2006 | 729 | 0.010 |
Why?
|
| Age Distribution | 1 | 2007 | 2902 | 0.010 |
Why?
|
| Point-of-Care Systems | 1 | 2010 | 1178 | 0.010 |
Why?
|
| Mass Screening | 1 | 2017 | 5253 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2007 | 1868 | 0.010 |
Why?
|
| Emergency Medical Services | 1 | 2012 | 1917 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 1991 | 3203 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2006 | 2726 | 0.010 |
Why?
|
| Cell Survival | 1 | 1991 | 5882 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 6896 | 0.010 |
Why?
|
| Cytokines | 1 | 1995 | 7323 | 0.010 |
Why?
|
| Medical Records | 1 | 2006 | 1413 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8385 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2017 | 4468 | 0.010 |
Why?
|
| Cloning, Molecular | 2 | 2001 | 4320 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 5321 | 0.010 |
Why?
|
| Protein Binding | 2 | 1995 | 9384 | 0.010 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2006 | 852 | 0.010 |
Why?
|
| Infant | 1 | 2021 | 35134 | 0.010 |
Why?
|
| Isoleucine | 1 | 1998 | 112 | 0.010 |
Why?
|
| GRB2 Adaptor Protein | 1 | 1998 | 103 | 0.010 |
Why?
|
| Exercise Test | 1 | 2006 | 2073 | 0.010 |
Why?
|
| Cell Fractionation | 1 | 1999 | 252 | 0.010 |
Why?
|
| Algorithms | 1 | 2019 | 13882 | 0.010 |
Why?
|
| Phospholipase C gamma | 1 | 1998 | 128 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2007 | 2016 | 0.010 |
Why?
|
| Blood Platelets | 1 | 1988 | 2509 | 0.010 |
Why?
|
| Antioxidants | 1 | 2006 | 1659 | 0.010 |
Why?
|
| Child | 2 | 2019 | 77709 | 0.010 |
Why?
|
| Eukaryotic Cells | 1 | 1999 | 198 | 0.010 |
Why?
|
| RNA Interference | 1 | 2006 | 2890 | 0.010 |
Why?
|
| Valine | 1 | 1998 | 413 | 0.010 |
Why?
|
| COS Cells | 1 | 1999 | 1161 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 12073 | 0.010 |
Why?
|
| Chickens | 1 | 1998 | 865 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2006 | 5077 | 0.010 |
Why?
|
| Intracranial Embolism and Thrombosis | 1 | 1996 | 148 | 0.010 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 1999 | 404 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2009 | 5388 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2006 | 2850 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 2916 | 0.010 |
Why?
|
| Dermatan Sulfate | 1 | 1995 | 35 | 0.010 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 6486 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1995 | 191 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 2282 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 2004 | 1373 | 0.010 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 1995 | 226 | 0.010 |
Why?
|
| Heart Rate | 1 | 2006 | 4092 | 0.010 |
Why?
|
| Plasmacytoma | 1 | 1995 | 183 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 9955 | 0.010 |
Why?
|
| Chemokine CXCL10 | 1 | 1995 | 305 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1999 | 1536 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 1995 | 315 | 0.010 |
Why?
|
| Genome, Human | 1 | 2007 | 4420 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 1999 | 2421 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1986 | 4554 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 1998 | 1227 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2006 | 5006 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1987 | 5023 | 0.010 |
Why?
|
| Leukotriene A4 | 1 | 1992 | 26 | 0.010 |
Why?
|
| Antipsychotic Agents | 1 | 2006 | 3057 | 0.010 |
Why?
|
| Glycosaminoglycans | 1 | 1995 | 624 | 0.010 |
Why?
|
| Calcimycin | 1 | 1992 | 222 | 0.010 |
Why?
|
| Japan | 1 | 1996 | 1360 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 4751 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1995 | 2050 | 0.010 |
Why?
|
| Parkinson Disease | 1 | 2005 | 2775 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2006 | 14561 | 0.010 |
Why?
|
| Homozygote | 1 | 1996 | 1787 | 0.010 |
Why?
|
| Obesity | 1 | 2013 | 12746 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 1992 | 329 | 0.010 |
Why?
|
| Rabbits | 1 | 1995 | 4894 | 0.010 |
Why?
|
| Gene Deletion | 1 | 1996 | 2751 | 0.000 |
Why?
|
| Heparin | 1 | 1995 | 1637 | 0.000 |
Why?
|
| Promoter Regions, Genetic | 1 | 1999 | 5867 | 0.000 |
Why?
|
| Tumor Cells, Cultured | 1 | 1995 | 6313 | 0.000 |
Why?
|
| Leukocytes | 1 | 1995 | 2045 | 0.000 |
Why?
|
| Chemical Precipitation | 1 | 1986 | 179 | 0.000 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1995 | 3773 | 0.000 |
Why?
|
| Isoelectric Point | 1 | 1986 | 80 | 0.000 |
Why?
|
| Binding Sites | 1 | 1995 | 6111 | 0.000 |
Why?
|
| Immunologic Techniques | 1 | 1986 | 219 | 0.000 |
Why?
|
| Quality of Life | 1 | 2007 | 12802 | 0.000 |
Why?
|
| Lymphoma | 1 | 1995 | 1877 | 0.000 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1986 | 1085 | 0.000 |
Why?
|
| Cell Compartmentation | 1 | 1986 | 402 | 0.000 |
Why?
|
| Subcellular Fractions | 1 | 1986 | 547 | 0.000 |
Why?
|
| Fibroblasts | 1 | 1995 | 4162 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1986 | 2255 | 0.000 |
Why?
|
| Proteins | 1 | 1998 | 6100 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1986 | 2505 | 0.000 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 15160 | 0.000 |
Why?
|
| Muscle Proteins | 1 | 1986 | 1158 | 0.000 |
Why?
|
| Lipid Metabolism | 1 | 1986 | 1889 | 0.000 |
Why?
|
| Membrane Proteins | 1 | 1986 | 7882 | 0.000 |
Why?
|